论文部分内容阅读
甲状腺相关性眼病(TAO)是一种器官特异性自身免疫性疾病,严重影响患者的生活质量。虽然本病使用糖皮质激素治疗具有远久的历史,但其不良反应干扰了临床上广泛应用。近年来,采用静脉脉冲治疗方案,并减少激素的用量,成为TAO治疗的新举措。此外,为防止Graves病采用放射性碘治疗导致突眼的发生或加重,也可适当采用小剂量的糖皮质激素。但是,临床工作中,使用这类药物仍然需要把握其适应证,并注意药物的剂量、疗程,防止其对肝脏等的毒性作用。
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease that seriously affects a patient’s quality of life. Although the disease with glucocorticoid therapy has a long history, but its adverse reactions interfere with the clinical application. In recent years, the use of intravenous pulse therapy programs, and reduce the amount of hormones, TAO treatment as a new move. In addition, in order to prevent the use of radioactive iodine treatment of Graves disease leading to the occurrence or exacerbation of exophthalmos, but also appropriate to use low-dose glucocorticoid. However, in clinical work, the use of such drugs still need to grasp the indications, and pay attention to the dose of drugs, medication, to prevent its toxic effects on the liver and so on.